NASDAQ:DJCO

Why Daily Journal Stock Is Sliding Even After a 25% Revenue Jump
····

Why Daily Journal Stock Is Sliding Even After a 25% Revenue Jump

Daily Journal Corp. shares fell 0.4% to $462.36 in Thursday afternoon Nasdaq trading, extending a two-day slide after reporting a $34.6 million quarterly net loss tied to $51.2 million in unrealized investment losses. Revenue rose 25% to $22.7 million, led by Journal Technologies. Trading volume was about 38,900 shares, with a market value near $637 million. The stock remained below its May 14 close after results were released.
May 21, 2026

Stock Market Today

  • Genomic Test Could Spare Millions of Breast Cancer Patients Chemotherapy, Landmark Study Finds
    May 29, 2026, 8:16 PM EDT. A landmark study reveals that millions of breast cancer patients could safely skip chemotherapy thanks to the Prosigna genomic test, which analyses tumor genes to assess recurrence risk. The international OPTIMA trial, involving 4,429 patients, showed a 93.7% five-year cancer-free survival rate for those who avoided chemotherapy, nearly matching the 94.9% rate for those treated with it. Karen Bonham, a trial participant, described her relief upon learning she would not need chemotherapy, attributing her cancer-free status nine years post-diagnosis to the test's guidance. Experts hail the findings as gamechanging, potentially transforming breast cancer treatment by reducing unnecessary chemotherapy and its side effects, while maintaining patient safety.